bioavailability
Parallel Screening - Can you afford to miss out?
January 16 by Pharmaceuticals & Biotechnology EditorImproving the bioavailability of poorly soluble new chemical entities is a leading challenge in drug development. Discover how parallel screening can ensure rapid determination of the most app...
The Search for New and Innovative Excipients – Possible Applications of Semi Fluorinated Alkanes
May 07 by René HolmA high proportion of the drug compounds in the innovative pharmaceutical companies have poor aqueous solubility or high metabolic ratio (Fahr and Liu, 2007; Hauss, 2007; Lipinski et al., 1997), whic...
Whitepaper: Phys.- Chem. Characterisation of NCEs in Pre-Formulation: Use of In silico Tools
October 10 by Pharmaceuticals & Biotechnology EditorAs solubility (or rather poor solubility) is one of the hot topics in drug development, there is a strong interest in gaining solubility data early on, at a stage of a project where there is still a...
Survey: Improving Solubility 2012
April 27 by Pharma IQ SurveysIn preparation for the 8th Annual Improving Solubility Summit, taking place in June, Pharma IQ would like to invite you to take part in a short survey. The survey consists of no more than 8 questions...
Steps to Expediting Time-to-Market for Insoluble Drug Candidates
March 15 by Niamh MadiganImproving the solubility of new chemical entities has proven to be one of the biggest hurdles to overcome in pharmaceutical drug development, and companies are always looking for new strategies for...
Maximizing Bioavailability and Expediting Time-to-Market for Poorly Soluble Drug Candidates
February 02 by Pharma IQPoorly soluble candidates now account for 60 percent of drugs in the pipeline, and as technologies become more complex, the figure continues to increase. Pharmaceutical companies are now stepping...
Predictions for Targeted Drug Delivery with David Elder and Brendan Griffin
December 05 by Andrea CharlesIn this Pharma IQ interview David Elder, Director of Product Development, GlaxoSmithKline and Brendan Griffin Lecturer in Pharmaceutics and Course Director University College Cork, discuss how th...
Drug Delivery Processes Look to Technology for Improvements
November 30 by Pharma IQAs with any industry, pharmaceutical firms are always looking for ways to improve drug formulation and delivery in order to enhance customer experience as well as cut costs and streamline processes....
Relationship Takes Priority Over Cost for 66.7% of Firms Using CROs for BE/BA Studies
July 08 by Pharma IQThe value of teamwork has been increasingly recognised by pharmaceutical companies in recent times. Research has shown that around two thirds now outsource their bioequivalence and bioavailability (...
A Third of Bioequivalence and Bioavailability Experts Find the Ability to Secure Biowaivers a Main Concern, Says Recent Pharma IQ Survey
June 30 by Pharma IQ NewsPharma IQ has just published the results of an industry-wide Bioequivalence and Bioavailability Survey, conducted recently among 2,000 bioequivalence and bioavailability experts. The results show...
Change Control, You’d Better Have One!
June 14 by Cristina FalcãoWhile Change Control (CC) is applied to the entire chain of events in any pharma industry, from R&D to batch release, it is the core function of any pharmaceutical plant. “Even when a c...
Does Your Bioavailability Need a Boost?
March 29 by Pharma IQOne of the major drug development hurdles is poor solubility, an estimated 40 percent of drugs are poorly soluble or insoluble in water1. As a result, a number of companies and partne...